Lirimar 20 mg - 10 Capsules

-Heterozygous familial hypercholesterolemia: High-intensity therapy: Oral: Initial: 40 or 80 mg once daily; if 40 mg once daily is initiated and tolerated, increase to 80 mg once daily. -Homozygous familial hypercholesterolemia: High-intensity therapy: Oral: 80 mg once daily. -Primary prevention of atherosclerotic cardiovascular disease: 1-Patients without diabetes, age 40 to 75 years, and LDL-C 70 to 189 mg/dL: a-In case of patients with ASCVD 10-year risk = 5% to <7.5%: Moderate-intensity therapy: Oral: 10 to 20 mg once daily to reduce LDL-C by 30% to 49%.b-In case of patients with ASCVD 10-year risk ≥7.5% to <20%: Moderate-intensity therapy: Oral: 10 to 20 mg once daily to reduce LDL-C by 30% to 49%. c-In case of patients with ASCVD 10-year risk ≥20%: High-intensity therapy: Oral: 40 to 80 mg once daily to reduce LDL-C by ≥50%. 2-While in case of patients with diabetes: a-In case of patients with age 40 to 75 years without additional ASCVD risk factors: Moderate-intensity therapy: Oral: 10 to 20 mg once daily to reduce LDL-C by 30% to 49%, b-in case of patients with ASCVD risk >20% or multiple ASCVD risk factors: High-intensity therapy: Oral: 40 to 80 mg once daily to reduce LDL-C by ≥50%. 3-Patients with LDL-C ≥190 mg/dL and age 20 to 75 years: High-intensity therapy: Oral: 40 to 80 mg once daily to reduce LDL-C by ≥50%. -Secondary prevention in patients with established atherosclerotic cardiovascular disease: High-intensity therapy: Oral: 80 mg once daily to reduce LDL-C by ≥50%. -Pediatric dosing: see dosage and administration